IRTC

Rating buyAI Memo

iRhythm

As of 2026-01-07/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-01-07 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

—

Key catalyst

Commercial rollout/expansion of AI-driven arrhythmia tools • 2026-06-30

Expected move: +97%

Biggest risk

Bear case assumes slower adoption, reimbursement headwinds, or execution issues that compress growth multiple and keep the stock near recent lows.

Invalidation

Break below $175 or thesis failure.

What would change my mind?

Bull case assumes successful commercial expansion of AI-enabled monitoring, favorable reimbursement wins, and accelerating revenue growth that justifies multiples nearer the high end of analyst estimates.

Research note

Recommendation

buy

Confidence

medium

As of

2026-01-07

Base target

$219

p=60%

Bull target

$256

p=20%

Bear target

$175

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Upcoming quarterly earnings (Q4/2025) and guidance
Reimbursement/market-share gains over 12 months
Bull case assumes successful commercial expansion of AI-enabled monitoring, favorable reimbursement wins, and accelerating revenue growth that justifies multiples nearer the high end of analyst estimates.

BearKey bullets

Competitive product introductions
Execution/supply-chain constraints
Regulatory or AI performance setbacks

WatchKey bullets

Commercial rollout/expansion of AI-driven arrhythmia tools

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $219 (p=60%)

Bull/Bear spread: +131% / +58%

Vs latest close: Bull +131% · Base +97% · Bear +58%

Scenario probabilities

Bull Target: $256 (p=20%)Base Target: $219 (p=60%)Bear Target: $175 (p=20%)

Commentary

Market commentary is cautiously positive: several consensus price-target aggregates show a constructive mean vs. the anchor, but dispersion is wide and execution risk remains [#SERP-2]. Recent analyst coverage skews toward Buy/Strong Buy in aggregates, reflecting optimism on growth and AI-enabled product adoption [#SERP-1].

As of 2026-01-07 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Bear case assumes slower adoption, reimbursement headwinds, or execution issues that compress growth multiple and keep the stock near recent lows.

Drivers

Scannable catalysts and supporting factors

Upcoming quarterly earnings (Q4/2025) and guidance
Reimbursement/market-share gains over 12 months

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-01-07Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$203.32

Range (USD)

$175.00 - $256.20

Count

Query: iRhythm Technologies Inc Common (IRTC) analyst consensus price target high low average

iRhythm Technologies Inc (IRTC) Stock Forecast & Price Target
Search result #1
According to projections from 15 analysts, the average 12-month price target for iRhythm Tech is 218.6, with a high estimate of 244 and a low estimate of 194.
Open source
iRhythm Technologies, Inc.: Target Price Consensus and Analysts ...
Search result #2
Analysts' Consensus ; Mean consensus. BUY ; Number of Analysts. 16 ; Last Close Price. 177.44USD ; Average target price. 218.60USD ; Spread / Average Target. +23.20%.
Extracted: $177.44, $218.60Open source
iRhythm Technologies, Inc. (IRTC) Stock Price, News, Quote & History
Search result #3
Price Target 194 -> 210. View More. Statistics: IRTC. View More. Valuation ... 0 Low. Sector Avg. 100 High. Research Reports: IRTC. View More. Daily – Vickers ...
Open source
Irhythm Technologies (IRTC) Stock Forecast, Price Targets and ...
Search result #4
The highest analyst price target is $244.00 ,the lowest forecast is $202.00. The average price target represents 26.03% Increase from the current price of $175 ...
Extracted: $244.00, $202.00, $175.00Open source
iRhythm Technologies Inc - IRTC Intrinsic Value - Alpha Spread
Search result #5
Wall Street analysts forecast IRTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRTC is ...
Open source
iRhythm Technologies (IRTC) Price Targets
Search result #6
The forecasts range from a low of $175.00 to a high of $244.00. The average price target represents an increase of 21.6% from the last closing price of $178.57.
Extracted: $175.00, $244.00, $178.57Open source

Scenarios

Bull Target (Scenario probability)

$256 / p=20% prob

Base Target (Scenario probability)

$219 / p=60% prob

Bear Target (Scenario probability)

$175 / p=20% prob

Price $111 as of 2026-07-17

Nearest Scenario: Bear (∆ 58%)

Targets vs latest close: Bull +131% · Base +97% · Bear +58%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-06-30
Commercial rollout/expansion of AI-driven arrhythmia tools
Broader adoption or a material commercial update for its AI/diagnostic platform could drive durable revenue growth; date is assumed conservatively as end of disclosed rollout window where only a window is public/uncertain [#SERP-4].
Prob 45.00% • Move 25.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

Upcoming quarterly earnings (Q4/2025) and guidance
2026-04-07
Quarterly results and management guidance may reprice shares; consensus analyst targets imply upside vs. current anchor, making the print a near-term catalyst for revision [#SERP-2].
Prob 70% • Move 12% • Priced-in 40%

Long-term Catalysts

Months to a year

Reimbursement/market-share gains over 12 months
2027-01-07
Sustained uptake, favorable reimbursement decisions, or partnerships could materially expand TAM and push valuation higher over a 12 -month horizon [#SERP-1].
Prob 55% • Move 40% • Priced-in 20%

Risks

Competitive product introductions
Execution/supply-chain constraints
Regulatory or AI performance setbacks
Reimbursement pressure or cuts
Slower-than-expected clinical adoption

Peers

Symbol	Summary
ABT	Abbott: larger med-tech with cardiac monitoring/device franchises and distribution scale; useful comparable for device-market dynamics.
BSX	Boston Scientific: broad electrophysiology and rhythm-management portfolio; competitor on clinician adoption and channels.
MDT	Medtronic: diversified cardiac device leader with deep clinical relationships that influence adoption trends.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: iRhythm Technologies Inc Common (IRTC) analyst consensus price target high low average
Analysis date: 2026-01-07

AI Stock Memo: IRTC - iRhythm - RankAlpha